Neuraxis, INC (NRXS): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Neuraxis, INC (NRXS) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers (e) Compensatory Arrangements of Certain Officers Stock Option Exchange As previously disclosed, on June 10, 2026, the stock
How this was made
The 30-second read
Why it matters
The filing represents a routine corporate compensation update with modest dilution; no immediate catalyst for price movement.
Market read
Primary relevance is limited to NRXS shareholders; the filing does not alter sector dynamics.
What to watch
Potential tax implications for executives and the timing of vesting may affect future cash flow.
Background
Neuraxis, Inc. filed a Form 8‑K reporting the cancellation of outstanding stock options and issuance of RSUs, plus new RSU grants to senior officers and directors.
Ticker impact
SEC 8‑K filing discloses conversion of 1.3M stock options to RSUs and new RSU grants to executives and directors.
minor downward pressure due to dilution, but likely muted as the amounts are modest for a micro‑cap.
The filing is a routine corporate action with no large cash component or strategic shift; market reaction is typically limited.
Market effects
None significant; compensation changes are company‑specific.
No broader regional effect.
Limited to investors in NRXS.
Counterpoint
If dilution concerns are overstated, the RSU grants could be seen as a positive signal of confidence from management.
Key entities
- ExecutiveBrian Carrico
President and CEO receiving RSUs.
- ExecutiveAdrian Miranda
Chief Medical Officer receiving RSUs.
- ExecutiveThomas Carrico
Chief Regulatory Officer receiving RSUs.
